Multiple Sclerosis - KOL Insight

US KOLs say TG Therapeutics' anti-CD20 mAb Briumvi is gaining momentum but European specialists struggle to see how it will impact use of Roche's Ocrevus or Novartis' Kesimpta - what underpins these diverse opinions? Why are experts intrigued by the novel mode of action of AB Science's pipeline tyrosine kinase inhibitor masitinib? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (10)

Treatment algorithm

Research objectives (124)

• Marketed drugs (62)
  • Oral disease-modifying therapies (11)
  • Second-generation sphingosine modulators (9)
  • Mavenclad (cladribine; Merck Group) (7)
  • Tysabri (natalizumab; Biogen) (9)
  • Ocrevus (ocrelizumab; Roche/Biogen) (10)
  • Kesimpta (ofatumumab; Novartis) (8)
  • Briumvi (ublituximab; TG Therapeutics) (8)
• Pipeline drugs (47)
  • Masitinib (AB Science) (9)
  • Evobrutinib (Merck Group) (11)
  • Tolebrutinib (Sanofi) (8)
  • Fenebrutinib (Roche) (6)
  • Remibrutinib (Novartis) (8)
  • Vidofludimus calcium (IMU-838; Immunic) (5)
• Earlier-stage approaches for MS (13)
  • Key insights summary (13)

Appendix (4)

• KOL details (4)
  • KOLs from North America (1)
  • KOLs from Europe (2)

KOL Bulletins